South Africa tightens rules on weight-loss drugs

South Africa is reviewing the rules for pharmacy compounding, the practice of preparing medicines outside the usual pharmaceutical manufacturing system. The proposed standards would address when pharmacies may make compound versions of treatments such as Ozempic and Mounjaro. This matters because regulators believe some pharmacies are producing medicines in bulk, rather than meeting a specific patient’s prescription or need.

The key example is a pharmacy making large quantities of a weight-loss or diabetes treatment before receiving individual patient orders. Pharmacy Council CEO Vincent Tlala described some businesses as “small-scale manufacturers.” The planned approach would draw a clearer line between patient-specific compounding and advance production of competing medicines.

The Pharmacy Council is working with the industry regulator on the changes. Guidelines are expected around March next year, after Novo Nordisk won a June court case against local pharmacies making unauthorized copies. High demand and the high price of branded products help explain why compound versions have emerged.

A compounded medicine is a preparation made by a pharmacy to meet an individual patient’s prescription or a specific medical need. It may involve combining, changing, or preparing ingredients in a form suited to that patient. This differs from a pharmaceutical company’s product, which is manufactured at industrial scale, packaged under a brand, and sold as a standardized medicine.

The important dividing line in this story is timing and purpose. A pharmacy compounding a medicine for a particular patient is different from producing large quantities before patients are identified. Vincent Tlala said some South African pharmacies had become “small-scale manufacturers,” which is the practice regulators want to examine.

The article does not provide a full technical or legal definition of compounding. It does show why the distinction matters: pharmacy-made versions of popular treatments compete with branded products, while South Africa prepares new standards and Novo Nordisk challenges unauthorized copies in court.

The article gives one striking measure of potential demand: 30% of adults in South Africa are obese. It identifies this as the highest adult obesity rate in Africa. That figure points to a substantial need for weight-management treatments, although the article does not convert it into a number of potential patients or estimate total sales.

Demand is not limited to weight loss. Ozempic and Mounjaro are also associated in the article with diabetes treatment, giving these medicines a second important use. The drugs are described as being in high demand in South Africa, while the cost of trademarked versions places them beyond the reach of most people.

That combination helps explain the growth of pharmacy-made alternatives and the regulatory pressure around them. Demand may remain strong, but the article does not predict future market size. It does indicate that affordability and obesity will continue shaping access and competition.

Regulators are concerned because compounding is meant to serve particular patients, while some pharmacies may be producing medicines ahead of individual demand. That changes the scale and nature of the activity. Instead of preparing a treatment for a specific prescription, a pharmacy could be making inventory for wider sale, resembling a drug manufacturer.

Vincent Tlala, chief executive of the South African Pharmacy Council, said some pharmacies had become, in effect, “small-scale manufacturers.” The concrete concern is that large quantities of treatments are being made in advance. The proposed standards would clarify where pharmacy compounding ends and manufacturing begins.

This issue matters especially for Ozempic and Mounjaro, which are popular weight-loss and diabetes treatments. Pharmacy-made versions compete with branded products from major drug companies. The Council is working with the industry regulator on new guidelines, expected around March next year, but the article does not specify penalties or detailed safety requirements.

Novo Nordisk and Eli Lilly are pharmaceutical companies, described in the article as giants behind blockbuster GLP-1 drugs. Novo Nordisk is associated with Ozempic, and Eli Lilly with Mounjaro. Their medicines target major demand for diabetes and weight-loss treatments in South Africa and internationally.

Their opposition has two connected reasons. Pharmacy-made products compete directly with their branded treatments, potentially taking sales from the companies. The article also refers to unauthorized copies, showing that the companies object when pharmacies make versions without permission. Novo Nordisk has already taken local compounding pharmacies to court.

The companies’ commercial pressure is strengthened by South Africa’s high demand and limited affordability. The country has Africa’s highest adult obesity rate, at 30%, but trademarked versions cost too much for most people. That gap encourages alternatives, while the companies seek tighter controls on pharmacy-made competitors.

Novo Nordisk’s June court victory was against local compounding pharmacies making unauthorized copies of its medicines. The ruling is important because it shows that pharmacy-made versions can face legal challenges from the company behind the branded treatment. It also supports the wider effort to control how compounding operates in South Africa.

The article does not describe the judgment’s exact remedy, such as a nationwide ban, damages, or a specific order against every pharmacy. Therefore, the clearest stated change is that Novo Nordisk successfully challenged unauthorized copying in court. The case did not, by itself, provide all the details of South Africa’s future compounding standards.

Its timing matters. The court victory came before the Pharmacy Council and industry regulator planned updated guidelines, expected around March next year. Together, the case and the proposed rules point toward closer scrutiny of pharmacies producing branded-drug alternatives in advance.

GLP-1 drugs are medicines that imitate the action of glucagon-like peptide-1, a hormone released after eating. This signal helps the pancreas release insulin when blood glucose is elevated and reduces the release of glucagon, which otherwise raises blood sugar. The overall effect is better blood-sugar control. The article identifies Ozempic and Mounjaro as popular weight-loss and diabetes treatments but does not explain this mechanism.

These medicines can also slow the movement of food from the stomach and increase feelings of fullness. That can reduce how much a person eats and help control body weight. Mounjaro also acts on another hormone pathway, but the article does not discuss that distinction. The central idea is that these treatments influence blood sugar and appetite through hormone-like signals.

In South Africa, demand is especially strong because adult obesity reaches 30%, the highest rate in Africa. However, branded versions are too expensive for most people, encouraging interest in pharmacy-made alternatives and sharpening the regulatory dispute.